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Abstract
Background: This article evaluates a single institute’s radiotherapy management of OSSN, a previously regarded as
rare malignancy, for possible future development of strategies to clearly define the role of adjuvant radiotherapy in
improving treatment outcomes.
Materials and methods: A retrospective review of 153 patients treated from January 2003 to December 2009.
Results: There was no difference in OSSN prevalence by gender (male to female ratio 1.07). Of 80/153 patients
tested 79 (98.8 %) were HIV positive. Most patients (62.9 %) had prior orbital exenteration. Moderately and poorly
differentiated grade (82.3 %) was associated with significantly higher stage and incidence of positive regional lymph
nodes. External beam therapy dose mostly used was 60Gy in 30 fractions at 200 cGy per fraction in 5 fractions per
week (34.8 %). 90Strontium therapy was given to 13.5 % (60Gy in 6 fractions at 10Gy per fraction weekly).
Favourable response (complete and partial) was seen in about 80 % of patients associated with higher total doses.
Regional lymph node positivity was associated with poorer outcome.
Conclusion: Adjuvant radiotherapy could have an important role in the management of patients presenting with
locally advanced OSSN who are mostly HIV positive in developing countries. Prospective studies to evaluate the
role of radiotherapy with or without chemotherapy in the management of OSSN in these settings are warranted.
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Background
Ocular surface squamous neoplasia (OSSN) has previ-
ously been considered to be a rare tumour mainly found
in elderly males [1, 2]. The incidence has been increas-
ing, especially in tropical and subtropical Africa [1]. This
trend has mostly been attributed to the high prevalence
of human immunodeficiency virus (HIV) and human
papilloma virus (HPV) infections. High solar radiation
has also been implicated in the pathogenesis of this dis-
ease in this region [3–6].
It has now become known as aggressive, affecting
young people equally for both genders [4]. In one study,
97 % of patients were found to be HIV positive, a sugges-
tion that ocular surface squamous neoplasia was an AIDS-
defining neoplasm with high morbidity and mortality [7].
The aggressiveness of this disease has been associated
with late stage disease requiring more aggressive surgery
in the form of enucleation and exenteration [8]. The local
recurrence rates for ocular surface squamous neoplasia
have been shown to be as high as 43 %, thus confirming
the need for consideration of adjuvant radiotherapy in this
disease, even if the margins of excision are negative [1, 9].
There have not been any randomised controlled clin-
ical trials reported in the literature on the management
of this disease, whether by radiotherapy or other means
[1]. Most of the reports in the literature pertaining to
the management of this disease are case reports and
most of those on radiotherapy treatment of ocular
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surface squamous neoplasia describe strontium 90
therapy [10, 11].
In this article a review of the radiotherapy manage-
ment of ocular surface squamous neoplasia including ex-
ternal beam therapy over a six-year period during high
HIV prevalence is presented. This is one of the largest
series of patients with this disease to be reported with
153 patients. The disease characteristics in relation to
histological features and stage of the disease in patients
presenting with ocular surface squamous neoplasia are
presented. The radiotherapy management of patients
with the disease is evaluated and information on the out-
come of management is provided. Recommendations for
the management of ocular surface squamous neoplasia
are also made based on results obtained.
The aim of the research reported in this article was to
assist in developing a better understanding of ocular
surface squamous neoplasia presenting with HIV disease
in order to develop prospective research strategies that
will contribute to clarifying the role of radiotherapy man-
agement of this disease and improving of outcomes of
treatment in the future.
Methods
This paper reports on a retrospective review of patients
who consecutively presented at the Parirenyatwa Radio-
therapy Centre, Harare, Zimbabwe. Radiotherapy treat-
ment records of patients presenting in the period
between 1 January 2003 and 31 December 2009 with a
diagnosis of OSSN were reviewed.
All patients presenting with histologically confirmed
OSSN during that period and were above the age of
18 years were eligible for participation in the study. Prior
to presentation, surgical intervention in the form of inci-
sional biopsy, simple local excision, enucleation or exen-
teration (partial and total) had been performed on the
patients as surgical management.
All patients without a histologically proven diagnosis
of SCC conjunctiva, patients under the age of 18 years
and patients referred without adequate required docu-
mentation were excluded. The information was obtained
from patient hospital records.
Outcome of treatment was recorded according to
whether there was complete response (no disease detected
clinically), partial response (good/favourable response),
stable disease (no change to size/symptoms of disease) or
disease progression (a notable increase in size of disease
or new lesions elsewhere) to treatment measured clinically
at follow up.
Follow up data was collected from the first docu-
mented visit after completion of treatment. All informa-
tion from the patient records were extracted on to a
designed extracted form. All data collected was quality
controlled for completeness of information through
crosschecking by at least 2 individuals. The data was en-
tered into EPI Info 3.5.3. All data entered was quality
controlled for data entry errors using SPSS version 16
and Epi Info 3.5.3. Data was then imported and analysed
in STATA version 10 and SPSS version 16.
Statistical analysis
Descriptive statistics were used to describe demographic
and disease characteristics. Trends were used to describe
the number of patients referred to the radiotherapy
centre over time and socio-demographic characteristics
over time. Chi-square tests were used for trend signifi-
cance and for association between categorical variables.
Statistical significance was defined at a p value of <0.05.
Ethical considerations
This research was carried out in accordance with the
principles of the Declaration of Helsinki. The research
protocol was submitted for consideration, comment and
guidance to the Joint Parirenyatwa Hospital and College
of Health Sciences Research Ethics Committee (JREC)
and was approved by that ethics body prior to conduct-
ing the research.
Results
In all, 153 patients’ records with this diagnosis were re-
trieved and formed the study population. The patients’
demographic characteristics, surgical/radiotherapy man-
agement, response to treatment and follow up will now
be discussed.
Out of the total of 153 patients, 79 (51.6 %) were male
and 74 (48.4 %) were female (male to female ratio 1.07).
The median age of the patients at presentation was
40 years with an interquartile range (IQR) of 36-48 years.
There was no statistically significant difference between
the number of male and females (p = 0.80) and this
remained so over the years of the study. The numbers of
patients seen showed an upward trend with relation to
time over the years as shown by the chi square test for
trend analysis (p = 0.03). Married patients constituted 78
(51.6 %) and 43 (28.1 %) of all the patients were widowed.
Table 1 summarizes the demographic characteristics of
the patients.
There was no difference in the proportions of rural
resident (47.7 %) and urban resident urban (45.1 %) pa-
tients with OSSN. No gender differences were demon-
strated between these 2 population groups.
HIV and antiretroviral (ART) status
The HIV status was established in 81/153 (53.0 %) of
these patients. The HIV positivity rate was 98.8 % (80/
81). Of the patients who tested positive, the CD4 count
was established in only 37 patients. The median CD4
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count was 122 cells per micro-litre with an interquartile
range (IQR) of 84-182 cells pre micro-litre.
The HIV status was unknown in 72/153 (47.1 %). Of
the patients with an unknown status 21/72 (29.10 %)
had either stigmata of HIV infection or reported having
an HIV-infected husband or young children alive or who
had died from an HIV-related illness.
Of the patients who were HIV positive only 34/80
(42.5 %) were on antiretroviral therapy (ART) at presen-
tation. Whilst none of the known HIV positive patients
were on ART at the start of the study in 2003, 13/25
(52 %) of known HIV positive patients were on ART by
2009. The median duration on ART prior to presenta-
tion was 12 weeks with an interquartile range (IQR) of
3-24 weeks.
Surgery and disease characteristics
Table 2 summarises the surgical interventions and path-
ology findings in the patients.
The commonest form of surgery performed was exen-
teration with 90 patients (58.8 %) having had total exen-
teration and 6 (3.6 %) patients having had partial
exenteration performed.
The common histological grades in 82.3 % of the study
patients were moderately and poorly differentiated squa-
mous cell carcinoma. Overall, 2 (1.3 %) patients were
found to have squamous cell carcinoma in the back-
ground of pterygium and 2 (1.3 %) patients in the study
had a spindle cell variant of squamous cell carcinoma.
Patients with poorly differentiated histological grade
were more likely to present with advanced stage disease
whereas those with other histological grades presented
with early stage disease (p = <0.001). Out of the 87 pa-
tients with stage 3 disease, 82 (94.3 %) had moderately
or poorly differentiated tumours.
Most of the 32 patients (17 or 53.1 %) who had simple
surgical excisions had positive margins whilst 39
(25.0 %) had unknown margins. There appeared to be
no relationship between the type of surgery and status of
margins of excision.
Of the 41 patients with positive regional lymph nodes
38 (90.2 %) had stage III and IV disease. Poorer histo-
logical grades were associated with the presence of posi-
tive lymph nodes (see Table 3). Clinical evaluation for
evidence of gross tumour in the orbit and regional
lymph nodes exhibited clinically evident disease in 82/
153 (53.6 %) patients.
Table 1 Demographic characteristics of OSSN patients
Characteristic N = 153 Percentage
Gender
Male 79 51.6 %
Female 74 48.4 %
Marital Status
Single 13 8.5 %
Married 78 51.6 %
Separated 8 5.2 %
Divorced 11 7.2 %
Widowed 43 28.1 %
Place of Residence
Rural 69 45,1 %
Peri-urban 11 7.2 %
Urban 73 47.7 %
Employment status
Unemployed 101 66.7 %
Informally employed 24 15.7 %
Formally employed 27 17.65
Table 2 Surgery and pathologic findings
Characteristic N = 153 Percentage
Type of surgery
Biopsy 10 6.6
Simple excision 32 20.9
Enucleation 15 9.8
Exenteration 90 58.8
Partial exenteration 6 3.9
Histology
Carcinoma in situ 5 3.3
Well differentiated 22 14.4
Moderately differentiated 92 60.1




















Ndlovu et al. Infectious Agents and Cancer  (2016) 11:18 Page 3 of 7
Patient treatment
Following initial evaluation 104/153 (67.97 %) patients
were offered treatment. Of those not offered treatment,
25/49 (16.3 %) defaulted review following the initial con-
sultation, 18/49 (11.8 %) were referred for further sur-
gery and were subsequently lost to follow-up. Six
patients (3.9 %) were lost to follow-up due to time delay
before starting treatment.
Of the 104 patients who received treatment, 89
(84.6 %) were prescribed external beam therapy whilst
14 (13.5 %) were prescribed strontium 90 therapy. Only
one patient was offered best supportive care.
Of those who received treatment 59 (56.7 %), patients
were considered for treatment with radical/curative
intent and 45 (43.3 %) patients were considered for pal-
liative treatment. Of patients prescribed radiotherapy
treatment 8 (7.8 %) failed to commence the treatment.
All 14 patients who were treated with strontium eye
applicator were prescribed 60 Gray (Gy) in six fractions
in six weeks (10 Gy per fraction weekly).
Table 4 summarises the doses prescribed for external
beam radiotherapy. External beam radiotherapy was
comprised of conventional 2D treatment.
The commonest prescribed dose was 60 Gy in 30 frac-
tions in 6 weeks (200 cGy per fraction). This was pre-
scribed for 31/89 (34.8 %) of the patients. Only one
patient was prescribed a single fraction of 600 cGy. The
other common prescriptions included 40 Gy in 15 frac-
tions in 3 weeks (266 cGy per fraction), 20 Gy in 5
fractions in 1 week (400 cGy per fraction) and 66 Gy in
33 fractions delivered over 6½ weeks (200 cGy per
fraction).
Anterior and lateral wedged pair orbital fields were
used to treat 77/89 (86.0 %) patients receiving external
beam radiotherapy. Ten patients (11.2 %) were treated
with a single anterior field either as a direct anterior or
anterior oblique field. The remaining 2 patients were
treated with non-standard fields with palliative intent
due to extensive disease.
Of the 103 patients who were prescribed and com-
menced radiotherapy 14 (13.6 %) did not complete treat-
ment. Of these 13 absconded, whilst only 1 had treatment
discontinued due to deterioration in performance status.
Of the 81 patients who received radiotherapy 78 (96.29 %)
completed within the prescribed time.
A total of 78 patients presented for follow up post-
treatment. The median follow-up was 6 weeks (IQR 6-
12 weeks). Of these patients 41 (52.6 %) had presented
with clinical disease and 37 (47.4 %) patients had not.
When the patients with clinical disease at the start of
treatment were assessed for response to treatment at
follow-up, 9/41 (22.0 %) had a complete response and
28/41 (68.3 %) had partial response. Disease progression
was seen in 4 (9.7 %) patients. The follow-up time
ranged from 2-52 weeks.
The majority of patients presenting for follow up
(82.9 %) had been treated with palliative intent. Four
(11.8 %) of these patients achieved a complete response.
Doses prescribed for these patients were 30 Gy in 10
fractions at 300 cGy per fraction 5 days per week (n = 2),
50 Gy in 20 fractions at 250 cGy per fraction 5 days per
week (n = 1) and the other 50 Gy in 25 fractions at
200 cGy per fraction 5 days per week. Five (71.4 %) pa-
tients treated with a curative intent achieved a complete
response and all 5 had been prescribed 60 Gy in 30 frac-
tions at 200 cGy per fraction.
The presence of regional lymph nodes was associated
with a poorer response to external beam radiotherapy
(see Table 5). Of the 23 patients who had regional lymph
node involvement, only 2 (8.7 %) had a complete
response to treatment. Seventeen (73.9 %) had a partial
response whilst 4 (17.4 %) had disease progression.
There was a statistically significant association between
Table 3 Histological grade versus regional lymph node (RLN) status
Histological grade Regional lymph nodes present Regional lymph nodes absent Total
Carcinoma in situ 0 (0 %) 5 (4.5 %) 5 (3.5 %)
Well differentiated 2 (4.9 %) 20 (17.9 %) 22 (14.4 %)
Moderately differentiated 25 (61 %) 67 (59.8 %) 92 (60.1 %)
Poorly differentiated 14 (34.1 %) 20 (17.9 %) 34 (22.2 %)
Total (% of total) 41 (25 %) 112 (75 %) 153 (100 %)
p value 0.03
Table 4 Prescribed doses for external beam
Prescribed dose a Frequency Percentage
Single fraction 600 cGy 1 1.1
30 Gy in 10 fractions at 300 cGy/fraction 22 24.7
37.50 Gy in 15 fractions at 250 cGy/fraction 3 3.4
45 Gy in 20 fractions at 225 cGy/fraction 2 2.2
50 Gy in 25 fractions at 200 cGy/fraction 6 6.7
50 Gy in 20 fractions at 250 cGy/fraction 16 18.0
60 Gy in 30 fractions at 200 cGy/fraction 31 34.8
Other 8 9.0
Total 89 100
Key – aexcept for single fraction treatment. Treatment was given five days
per week
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a positive regional lymph node status and poor response
rate (p = 0.002).
A favourable response (complete and partial) for the
patients with clinical initially evident disease was associ-
ated with higher total dose of radiotherapy delivered.
Doses above 37.5 Gy in 15 fractions delivered at
250 cGy in 3 weeks achieved either a complete response
or partial response (see Table 6).
Of the patients presenting without clinical disease
35(91.6 %) were free of recurrence and 2 (5.4 %) had dis-
ease recurrence during follow-up. The maximum follow-
up was 60 weeks and the minimum follow-up was
2 weeks.
Overall, these results pertained to this population of
relatively young, mostly HIV positive patients who had
advanced OSSN treated postoperatively mainly with ex-
ternal beam radiotherapy and with Strontium therapy.
Results of treatment were largely favourable with
favourable response associated with higher radiotherapy
doses. Regional node positivity was associated with a
poorer response to treatment. Post treatment follow up
was not optimal.
Discussion
OSSN is the most common malignancy of the conjunctiva
[4]. Its association with HIV infection as well as other
causes of immunosuppressive disorders such as has been
demonstrated in transplant patients and systemic lupus
erythematosus (SLE) is documented [8, 10, 12]. Current
clinical practice for the treatment of OSSN is based on a
weak evidence base. This evidence has been largely
attained from case reports and case series [1].
The results were in keeping with a lower age at pres-
entation and lack of male preponderance that has been
demonstrated in other settings of high HIV infection
prevalence [5, 13]. In this research the HIV positivity
rate was 98.8 % in those patients who were tested. This
is in keeping with previously reported rates in the re-
gion. Nearly half of the patients in this study were not
tested for HIV due to non-mandatory testing being the
norm during the study period. It has however been
clearly demonstrated that an HIV prevalence above 90 %
is common in this cancer [4, 7]. The impact of the use
of ART on the natural history of the disease in these pa-
tients remains to be seen. This research was carried out
during a period of low ART uptake.
It has been previously shown, as in this research, that
larger tumours such as those seen in patients with HIV
infection tend to be invasive, need more extensive sur-
gery, and frequently recur after surgery [4, 8, 14, 15].
This raises the question of what adequate initial surgery
should be performed and what criteria to use to initiate
adjuvant radiotherapy or other therapies following surgi-
cal intervention [9, 14].
Most patients used as a sample in this research had
advanced stage and moderately or poorly differentiated
tumours. These characteristics are likely to account for
the high rate of enucleation and exenteration (72.5 %
combined). An increase the likelihood of local recur-
rence following surgery has been previously demon-
strated [14]. If it is the case this further builds on to the
need for postoperative radiotherapy.
Management of regional lymph nodes in OSSN is yet
to be clearly defined. In this research, the association be-
tween poorer differentiated and involved lymph nodes
may suggest the need to explore what would be ad-
equate nodal management in OSSN by stage and grade
of tumour. Sentinel lymph node biopsy may be one such
approach [16].
Whilst this research reports on postoperative radio-
therapy treatment of OSSN other modalities of treat-
ment have been considered. At the centre chemotherapy
was not used post-operatively. Documented interventions
include immunotherapy [8, 17], photodynamic therapy
[18], and topical chemotherapy [9, 19].
Reports on the radiotherapy management of OSSN in
the literature are mostly on strontium 90 therapy for
Table 5 Regional lymph node (RLN) status versus clinical
response to treatment
RLN Response rate
Complete Partial Progression Total
Present 2 (8.7 %) 17 (73.9 %) 4 (17.4 %) 23 (100 %)
Absent 7 (38.9) 11 (61.1 %) 0 (0.0 %) 18 (100 %)
Total 9 28 4 41
Table 6 Response rate of clinically detected disease by total
dose delivered
Response rate
Total dose delivered a Complete Partial Progression Total
Single fraction 0 0 1 1
30 Gy in 10 # 2 15 1 18
20 Gy in 5 # 0 1 2 3
37.5 Gy in 15 # 0 2 0 2
45 Gy in 20 # 0 1 0 1
40 Gy in 15 # 0 1 0 1
40 Gy in 20 # 0 1 0 1
50 Gy in 20 # 1 1 0 2
50 Gy in 25 # 1 1 0 2
54 Gy in 27# 0 1 0 1
60 Gy in 6 #b 2 0 0 2
60 Gy in 30 # 3 4 0 7
Total 9 28 4 41
Key - a # = fractions given at 5 fractions per week; b patients who received
strontium therapy
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superficial lesions [10, 11]. A number of dose and fraction-
ation schedules have been previously reported for stron-
tium 90 therapy, with some authors giving doses as high
as 60 Gy in a single fraction and 140 Gy in 7 fractions
[10]. In this research, 60 Gy at 10 Gy per fraction per week
in 6 weeks was used for all patients receiving strontium 90
treatment.
Few case series have been published on the use of
other radiotherapy modalities including electron external
beam treatment [20] and plaque brachytherapy [21].
Electron beam radiotherapy has been used in one reported
case to preserve eyesight in recurrent disease [22]. Simi-
larly in another case report proton beam therapy was used
in 2 cases of extensive disease preoperatively [23].
The more frequent use of external beam therapy com-
pared with strontium 90 reported in this research
(84.6 % versus 13.5 %) can be attributed to the dictates
of the disease characteristics in our patients. In this re-
search, photon external beam treatment was given using
general guidelines for the use of orbital treatment fields.
This retrospective study that was carried out in a low
resource setting had limitations, one being poor follow
up of patients after treatment. This limited the acquisition
of information on long-term outcomes and treatment
complications.
Some of the findings of this study are in keeping with
what has been documented from similar high HIV
prevalence settings. The use of external beam radiother-
apy in similar patients has however not been commonly
reported.
Conclusion
Radiotherapy treatment in OSSN – and in a high HIV
prevalence environment particularly, has a role to play
due to the tumour characteristics in such patients. This
is clearly demonstrated in the research reported in this
article by the high overall response rate to this treat-
ment. With OSSN increasingly affecting young adults
and causing substantial morbidity and mortality, it be-
comes important to further study what the optimum in-
terventions are.
There currently is no evidence based practice guideline
on the management of this disease in both HIV positive
and negative patients. Most clinical management is based
on case reports. This is one of the largest series of patients
with OSSN reported in the literature and it has shown the
positive impact of radiotherapy in advance disease.
There is a significant association between HIV infection
and development of OSSN. Radiotherapy could play an
important role in the management of patients presenting
with locally advanced disease. Prospective studies could
establish the role of radiotherapy with or without chemo-
therapy and regional lymph node surgery in this patient
population.
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